Pradaxa Lawsuit Update: FDA Releases Report on Pradaxa Bleeding
As Pradaxa lawsuits continue to mount, an FDA report finds the Pradaxa bleeding risk is similar to that of warfarin, but fails to address the lack of an antidote for serious Pradaxa hemorrhaging, Bernstein Liebhard LLP reports.
New York, NY (PRWEB) November 05, 2012
Nearly one year after launching a safety review of Pradaxa, the U.S. Food & Drug Administration (FDA) has released a report finding that Pradaxa does not appear to pose a higher risk of serious internal bleeding compared to warfarin, Bernstein Liebhard LLP reports.* However, a report published by The New York Times points out that the FDA failed to address the lack of a reversal agent for Pradaxa bleeding. By contrast, sudden hemorrhaging caused by warfarin can be stopped via the administration of vitamin K.**
“A key allegation of the Pradaxa lawsuits is that the lack of an antidote for Pradaxa bleeding makes this drug far more dangerous than warfarin,” says Bernstein Liebhard LLP, a national law firm representing clients who have been injured by dangerous drugs and defective medical devices. The firm is currently offering free and confidential lawsuit evaluations to individuals who suffered serious Pradaxa side effects.
According to The New York Times report, Pradaxa was approved to prevent strokes in people with a heart-rhythm disorder known as atrial fibrillation. In its two years on the market, Pradaxa has garnered more than $1 billion in sales for its maker, Boehringer Ingelheim. However, in that short time period, the drug has been linked to more than 500 cases of fatal bleeding in the U.S., the Times said.
Scores of people throughout the country have filed Pradaxa lawsuits alleging Boehringer Ingelheim failed to adequately warn patients and prescribing physicians of the risks associated with Pradaxa. In August, the U.S. Judicial Panel on Multidistrict Litigation (JPML) ordered that all federally-filed Pradaxa lawsuits be consolidated in a multidistrict litigation in U.S. District Court, Southern District of Illinois (In Re: Pradaxa Product Liability Litigation, MDL No. 2385).***
Victims of serious episodes of Pradaxa bleeding may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing a Pradaxa lawsuit by visiting Bernstein Liebhard LLP's website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs' Hot List,” recognizing the top plaintiffs' firms in the country, for the past 10 consecutive years.
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebPradaxa-Lawsuits/Pradaxa-Bleeding/prweb10095838.htmView Comments and Join the Discussion!